Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month Low at $28.77

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as $28.77 and last traded at $28.96, with a volume of 158220 shares changing hands. The stock had previously closed at $29.28.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on SUPN shares. StockNews.com cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. Piper Sandler dropped their price objective on Supernus Pharmaceuticals from $46.00 to $43.00 in a research report on Wednesday, July 26th.

Supernus Pharmaceuticals Stock Down 0.2 %

The firm has a 50 day moving average price of $30.99 and a 200 day moving average price of $33.67. The stock has a market cap of $1.60 billion, a P/E ratio of 40.04 and a beta of 1.02.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.23 by ($0.25). The company had revenue of $135.56 million during the quarter, compared to the consensus estimate of $143.63 million. Supernus Pharmaceuticals had a return on equity of 4.86% and a net margin of 6.84%. The firm’s quarterly revenue was down 20.3% compared to the same quarter last year. During the same period last year, the business earned $0.14 EPS. Equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current fiscal year.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Tami Tillotson Martin sold 8,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $32.00, for a total transaction of $259,200.00. Following the completion of the transaction, the vice president now owns 85,249 shares in the company, valued at approximately $2,727,968. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.76% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of SUPN. Glass Jacobson Investment Advisors llc purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $30,000. Public Employees Retirement System of Ohio boosted its holdings in shares of Supernus Pharmaceuticals by 41.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 368 shares during the period. Mendota Financial Group LLC purchased a new position in shares of Supernus Pharmaceuticals in the 1st quarter worth approximately $46,000. Tower Research Capital LLC TRC boosted its holdings in shares of Supernus Pharmaceuticals by 389.7% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,327 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 1,056 shares during the period. Finally, Group One Trading L.P. boosted its holdings in shares of Supernus Pharmaceuticals by 103.6% in the 4th quarter. Group One Trading L.P. now owns 1,499 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 43,303 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.